Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

StockNews.com

Obesity drug boom pushes Novo Nordisk shares to record high

Market value of Danish drugmaker behind Wegovy and Ozempic tops $500bn as demand soars

The Guardian - UK

Weight-loss Drug Maker Novo Nordisk's Profit Surges As Sales Boom

Danish pharmaceutical giant Novo Nordisk posted bumper profits for 2023 on Wednesday, driven by blockbuster sales of diabetes and obesity treatments that helped it become Europe's most valuable company.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

UK house prices rise in January, Novo Nordisk obesity drug sales surge – as it happened

Nationwide says housing market looks ‘more positive’ as prices rise 0.7%; the Danish maker of Ozempic and Wegovy predicts further strong growth in 2024

The Guardian - UK

2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter

Five pharma companies will have sales that exceed $50 billion this year.

Kiplinger

"Faux-zempic" driving hospitalizations

Experts warn against the risks of illegitimately obtained Ozempic and Wegovy

Salon

3 Pharma Stocks for January 2024 Profits

The pharmaceutical industry is thriving, fueled by steady demand for drugs, cost-efficient alternative discoveries, and rapid technological innovations. Hence, fundamentally strong pharma stocks Novo Nordisk (NVO), Eton Pharmaceuticals (ETON), and Pacira BioSciences (PCRX) might be profitable buys now. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Will weight loss drugs kill the fast food business?

Many firms see the dire forecasts as ‘overblown’ but they know they will have to adapt products to make ‘every bite counts’

The Guardian - UK

Ozempic and Wegovy Show Lower Risk of Suicidal Thoughts

Hold onto your hats, folks, because there's some fascinating news in the world of diabetes and obesity drugs! A recent federal study found that people taki...

Top News

FDA Seizes Thousands of Counterfeit Ozempic Shots for Diabetes

Counterfeit Ozempic diabetes drug seized by FDA, prompting concerns over identity, quality, and safety. Report suspect packages to FDA hotline.

Cycling Weekly

'I had to set two alarms at night to check my glucose to make sure I wouldn’t die': meet the revolutionary who won't stop until cycling is safer

The UCI banned his technology from races, yet Supersapiens boss Phil Southerland tells Chris Marshall-Bell he is still dead set on changing the sport in the most profound way for decades

The Independent UK

Weight loss from Lilly’s Zepbound drug reversed after stopping treatment, according to study

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

Chasing Weight Loss Dream, Many In US Seek Ozempic Alternatives

Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.

Fortune

Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs

Weight-loss drug Wegovy faces high demand, limited supply, and tricky health care systems to navigate.

Barchart

3 Buy-Rated Healthcare Dividend Stocks for Income Investors

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

The Guardian - UK

Revealed: obesity jab maker discussed targeting benefit claimants with UK government

Drug firm Novo Nordisk proposed singling out those most likely to return to work with its weight-loss injection

Fortune

Germany considers banning Ozempic exports, including to U.S.

Germany exports Ozempic to the EU and the U.S., Karl Broich, president of the German Federal Institute for Drugs and Medical Devices, told Der Spiegel.

Fortune

Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports

Wegovy was found to cut the risk of serious heart events by 20%—Novo Nordisk has now asked the U.S. FDA to reflect the heart benefits in the drug's label.

The Independent UK

Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds

A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients

1 … 16 17 18 19

People

Steve Barclay

1,167 stories

Dipanjan BanchurSince

Lars Fruergaard Jørgensen

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.